Anti-cancer immune responses to DNA damage response inhibitors: Molecular mechanisms and progress toward clinical translation

DNA damage response inhibitors are widely used anti-cancer agents that have potent activity against tumor cells with deficiencies in various DNA damage response proteins such as BRCA1/2. Inhibition of other proteins in this pathway including PARP, DNA-PK, WEE1, CHK1/2, ATR, or ATM can sensitize canc...

Descripción completa

Detalles Bibliográficos
Autores principales: Carlsen, Lindsey, El-Deiry, Wafik S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9583871/
https://www.ncbi.nlm.nih.gov/pubmed/36276148
http://dx.doi.org/10.3389/fonc.2022.998388

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9583871/
https://www.ncbi.nlm.nih.gov/pubmed/36276148
http://dx.doi.org/10.3389/fonc.2022.998388

Ejemplares similares